MultiHance
Total Payments
$340,659
Transactions
63
Doctors
21
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $92.34 | 1 | 1 |
| 2023 | $46,166 | 6 | 4 |
| 2022 | $73,488 | 13 | 9 |
| 2021 | $82,635 | 10 | 3 |
| 2020 | $138,277 | 33 | 5 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $322,950 | 37 | 94.8% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $6,000 | 2 | 1.8% |
| Consulting Fee | $3,500 | 3 | 1.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,500 | 1 | 1.0% |
| Education | $2,418 | 4 | 0.7% |
| Travel and Lodging | $1,153 | 2 | 0.3% |
| Food and Beverage | $1,138 | 14 | 0.3% |
Payments by Type
Research
$322,950
37 transactions
General
$17,709
26 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| An Autopsy Tissue Study For Quantification Of Gadolinium Levels And Histhopathological Changes From Subjects Who Received a Gadolinium-Based Contrast Agent (MULTIHANCE, GADAVIST, DOTAREM, OR PROHANCE) | Bracco Diagnostics Inc. | $93,535 | 0 |
| AN AUTOPSY TISSUE STUDY FOR QUANTIFICATION OF GADOLINIUM LEVELS AND HISTHOPATHOLOGICAL CHANGES FROM SUBJECTS WHO RECEIVED A GADOLINIUM-BASED CONTRAST AGENT (MULTIHANCE, GADAVIST, DOTAREM, OR PROHANCE) | Bracco Diagnostics Inc. | $67,759 | 0 |
| Capability of Artificial Intelligence to Detect Malignancy in Low Dose Breast MRI | Bracco Diagnostics Inc. | $66,667 | 0 |
| IIS-US-106 | Bracco Diagnostics Inc. | $40,691 | 0 |
| Wang Jin-Intraindividual comparison of MultiHance at the dose of 0.05 mmol/kg and Primovist at the dose of 0.025 mmol/kg in terms of diagnostic performance for detection of hepatocellular carcinoma (HCC) nodules | Bracco Diagnostics Inc. | $25,000 | 1 |
| AN AUTOPSY TISSUE STUDY FOR QUANTIFICATION OF GADOLINIUM LEVELS AND HISTHOPATHOLOGICAL CHANGES FROM SUBJECTS WHO RECEIVED A GADOLINIUM-BASED CONTRAST AGENT (MULTIHANCE, GADAVIST, DOTAREM, OR PROHANCE) | BRACCO DIAGNOSTICS INC. | $13,750 | 1 |
| THE SAFETY AND EFFICACY OF PROHANCE AT THE DOSE OF 0.10 MMOL/KG IN MAGNETIC RESONANCE IMAGING OF THE CENTRAL NERVOUS SYSTEM IN PEDIATRIC PATIENTS WHO ARE YOUNGER THAN 2 YEARS OF AGE | Bracco Diagnostics Inc. | $10,168 | 0 |
| IIS-US-136 | Bracco Diagnostics Inc. | $5,381 | 0 |
Top Doctors Receiving Payments for MultiHance
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Baltimore, MD | $286,200 | 36 |
| , MD | Diagnostic Radiology | Omaha, NE | $25,681 | 3 |
| , M.D | Neuroradiology | Guaynabo, PR | $13,750 | 1 |
| Alessandro Furlan | Diagnostic Radiology | Pittsburgh, PA | $3,500 | 1 |
| , MD | Diagnostic Radiology | Grand Rapids, MI | $3,126 | 2 |
| , MD | Diagnostic Radiology | Trevose, PA | $3,000 | 1 |
| , MD | Diagnostic Radiology | Los Angeles, CA | $1,500 | 1 |
| , MD | Diagnostic Radiology | Philadelphia, PA | $1,000 | 1 |
| , M.D | Diagnostic Radiology | La Jolla, CA | $1,000 | 1 |
| , M.D | Diagnostic Radiology | Durham, NC | $798.85 | 2 |
| , MD | Specialist | Pittsburgh, PA | $417.83 | 3 |
| , MD | Neuroradiology | Middleton, WI | $236.03 | 1 |
| , MD, PHD | Diagnostic Radiology | San Diego, CA | $94.87 | 1 |
| , M.D | Diagnostic Radiology | Phoenix, AZ | $92.34 | 1 |
| , MD | Diagnostic Radiology | Boise, ID | $61.41 | 1 |
| , MD | Diagnostic Radiology | Grand Rapids, MI | $59.57 | 1 |
| , MD, PHD | Neuroradiology | Stanford, CA | $26.50 | 1 |
| , M.D | Diagnostic Radiology | Akron, OH | $26.46 | 1 |
| , M.D | Diagnostic Radiology | Sacramento, CA | $26.46 | 1 |
| , MD | Diagnostic Radiology | Cleveland, OH | $26.46 | 1 |
| , MD | Diagnostic Radiology | Williamsville, NY | $19.90 | 1 |
| , MD | Diagnostic Radiology | Tampa, FL | $15.21 | 1 |
Ad
Manufacturing Companies
- Bracco Diagnostics Inc. $318,962
- BRACCO DIAGNOSTICS INC. $21,697
Product Information
- Type Drug
- Total Payments $340,659
- Total Doctors 21
- Transactions 63
About MultiHance
MultiHance is a drug associated with $340,659 in payments to 21 healthcare providers, recorded across 63 transactions in the CMS Open Payments database. The primary manufacturer is Bracco Diagnostics Inc..
Payment data is available from 2020 to 2024. In 2024, $92.34 was paid across 1 transactions to 1 doctors.
The most common payment nature for MultiHance is "Unspecified" ($322,950, 94.8% of total).
MultiHance is associated with 8 research studies, including "An Autopsy Tissue Study For Quantification Of Gadolinium Levels And Histhopathological Changes From Subjects Who Received a Gadolinium-Based Contrast Agent (MULTIHANCE, GADAVIST, DOTAREM, OR PROHANCE)" ($93,535).